Brought to you by 
Spark Therapeutics nets $128mm through public stock sale
28 Jun 2016
Executive Summary
Spark Therapeutics Inc. (gene therapies for genetic conditions including retinal, liver-related, and neurodegenerative diseases) netted $128mm through the public sale of 3mm common shares (including the overallotment) at $45. Selling stockholder the Children's Hospital of Philadelphia (CHOP) also sold 1mm shares. Some of the proceeds will fund development of preclinical candidate SPK-FVIII (for hemophilia A) and activities related to the future launch of voretigene neparvovec for RPE65-mediated inherited retinal diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spark Therapeutics nets $128mm through public stock sale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice